Klaus Langer

Title: Klaus Langer: Innovator in Photodynamic Therapy

Introduction

Klaus Langer, an accomplished inventor based in Münster, Germany, has made significant contributions to the field of medical technology. His innovative work focuses on creating advanced nanoparticle carrier systems aimed at enhancing photodynamic therapy, a treatment modality used in oncology.

Latest Patents

Langer holds a patent for "Nanoparticle carrier systems based on human serum albumin for photodynamic therapy." This invention details compositions that are stable in storage and methods for producing pharmaceutical nanoparticulate formulations. The formulations utilize a hydrophobic photosensitizer and human serum albumin (HSA), making them suitable for parenteral administration. Notably, the nanoparticle formulations effectively deliver photosensitizers such as tetrapyrrole derivatives, addressing therapeutic needs in the treatment of hyperplastic and neoplastic conditions, particularly targeting tumor cells.

Career Highlights

Klaus Langer is associated with Biolitec Pharma Marketing Ltd, a company specializing in innovative medical solutions. His work is pivotal in advancing pharmaceutical formulations that improve the efficacy and safety of photodynamic therapy. His dedication to research and innovation has established him as a key figure in the field.

Collaborations

Throughout his career, Langer has collaborated with notable individuals in the industry, including Matthias Wacker and Beate Röder. These collaborations have fostered a creative environment for developing groundbreaking therapeutic solutions, enhancing the potential for improved patient outcomes.

Conclusion

Klaus Langer's contributions to nanoparticle systems in photodynamic therapy highlight the importance of innovation in medical treatments. His work not only enhances the effectiveness of therapeutic agents but also exemplifies the transformative power of invention in healthcare. As a prominent figure in the biomedical sphere, Langer continues to inspire future advancements in this critical field.